Table 2.
Safety summary.
| Patients with at Least 1, n (%) | Arm B | Arm C | Arm D |
|---|---|---|---|
| Atezo + IFNα | Atezo + PEG-IFNα | Atezo + PEG-IFNα + Bev | |
| (n = 65) | (n = 6) | (n = 45) | |
| Treatment-emergent AE of any grade | 65 (100) | 6 (100) | 45 (100) |
| Treatment-emergent AE with fatal outcome | 3 (4.6) | 0 | 1 (2.2) |
| Serious treatment-emergent AE | 19 (29.2) | 4 (66.7) | 19 (42.2) |
| Treatment-emergent Grade 3–5 AE | 25 (38.5) | 3 (50.0) | 28 (62.2) |
| AE leading to drug withdrawal | |||
| AE leading to atezo withdrawal | 3 (4.6) | 1 (16.7) | 1 (2.2) |
| AE leading to IFNα withdrawal | 3 (4.6) | – | – |
| AE leading to PEG-IFNα withdrawal | – | 1 (16.7) | 2 (4.4) |
| AE leading to bev withdrawal | – | – | 8 (17.8) |
| AE leading to drug dose modification/interruption | |||
| AE leading to atezo dose interruption | 13 (20.0) | 2 (33.3) | 7 (15.6) |
| AE leading to IFNα dose modification/interruption | 7 (10.8) | – | – |
| AE leading to PEG-IFNα dose modification/interruption | – | 2 (33.3) | 6 (13.3) |
| AE leading to bev dose interruption | – | – | 11 (24.4) |
AE, adverse event; atezo, atezolizumab; bev, bevacizumab; IFNα, interferon-α; PEG, polyethylene glycol.